NIFTY 50

Novartis to buy AveXis for $8.7 billion

Updated : April 09, 2018 10:55 AM IST

The Novartis offer represents a premium of 88% to AveXis’ closing price on April 6, 2018.
AveXis' drug AVXS-101 granted orphan drug designation, approval and launch expected in 2019.
Novartis to buy AveXis for $8.7 billion
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more

You May Also Like

Live TV